Mizuho analyst Anthony Petrone raised the firm’s price target on LivaNova to $60 from $53 and keeps a Neutral rating on the shares. The company reported a “surprising” beat in Q2, driven by outperformance in neuromodulation and cardiopulmonary segments, which saw broad strength in all regions, the analyst tells investors in a research note. The firm, however, remains Neutral ahead of the CEO switch and pipeline readouts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LIVN: